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Abstract
Introduction and Aims. Indigenous Australians experience a signiﬁcant gap in life expectancy compared with non-Indigenous
Australians. Indigenous communities have high-smoking prevalence and low engagement with cessation therapies. This qualitative
research, conducted in an urban Australian Indigenous community, explored smokers’ views on smoking, quitting and engagement
with current nicotine replacement therapies. Opinions on acceptability of tobacco harm reduction were sought. We explored the
acceptability of novel nicotine products, that is, new or unfamiliar products, including non-therapeutic options, such as e-
cigarettes. Design and Methods. Focus groups and individual interviews with adult Indigenous daily smokers (n = 27) were
used. Current and novel nicotine products were displayed and demonstrated. Discussions were audio-recorded, transcribed and
analysed thematically. Results. Participants expressed interest in trying existing and novel nicotine products. Short-to-medium
term use of nicotine replacement therapy for quitting was generally acceptable; views on long-term use were mixed. Interest in use
of tobacco substitutes depended on their perceived effectiveness, providing a ‘kick’ and ‘relieving stress’. Desirable qualities for tobacco
substitutes were identiﬁed with gender differences and product preferences noted. The unpleasant taste of existing products is a barrier
to both short-term and long-term use. Discussion. We found substantial interest in trying some existing and novel nicotine
products, mostly for short-term use. A number of attributes were identiﬁed that would make nicotine products potentially acceptable
as a long-term substitute. Conclusions. Some participants were interested in long-term substitution if acceptable products were
available. Improvements in current products and access to novel products are needed if tobacco harm reduction is to be acceptable.
[Yuke K, Ford P, Foley W, Mutch A, Fitzgerald L, Gartner C. Australian urban Indigenous smokers’ perspectives on
nicotine products and tobacco harm reduction. Drug Alcohol Rev 2017;00:000-000]
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Introduction
Smoking is a leading contributor to disease burden
among Indigenous Australians, causing approximately
20% of Indigenous deaths and 17% of the gap in life
expectancy between Indigenous and non-Indigenous
Australians [1]. While Indigenous smokers are just as
interested in cessation as other Australian smokers, they
are less likely to attempt to quit or to sustain abstinence
for at least 1 month [2]. The social determinants of
health, including education, employment, high levels of
stress and trauma, cultural practices, and social norms,
including the socially embedded nature of smoking, are
associated with the persistence of smoking in Indigenous
communities [3–5].
The Australian Government set a target of halving the
Indigenous smoking rate from the 2008 rate of 47.7% by
2018 [6]. Population level tobacco control policies,
including taxation, plain packaging, advertising and
smoke-free areas, have effectively reduced tobacco
consumption in the general population [7], but there is
limited evidence of effectiveness among Indigenous
peoples [8–10]. Available cessation assistance includes
counselling delivered by Quitline or a health worker,
nicotine replacement therapy (NRT) and prescription
medications (Bupropion and Varenicline). Some are free
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or subsidised through thepharmaceutical beneﬁts scheme
and the ‘close the gap’ initiative, such as nicotine patches
[11], but most NRTs must be purchased by the client.
Some Aboriginal medical services also self-fund non-
subsidised NRT [12]. Despite access and affordability,
Indigenous Australian smokers are less likely to use
cessation aids than other Australian smokers [5,13].
Indigenous smoking rates are declining, but new
approaches are needed to close the health gap. One
approach that has not been used in Australia, but is
gaining attention elsewhere, is tobacco harm reduction
(THR) [14,15], deﬁned as ‘decreasing the burden of
death and disease, without completely eliminating
nicotine and tobacco use’ [16]. An example of THR is
the uptake of a non-smoked tobacco product (snus)
among Swedish men that was associated with decreased
smoking and tobacco-related disease [16,17]. Few
smokers outside Nordic countries appear interested in
using snus [18], but new non-therapeutic nicotine
products, such as e-cigarettes appear to have widespread
appeal [15]. THR may be a potentially useful approach
for heavily dependent smokers, including those from
disadvantaged populations [16] who use cigarettes to
address high levels of daily stress [19]. Therefore, THR
may have relevance to Indigenous smokers to
supplement abstinence-focussed approaches. However,
it is unknown if Indigenous smokers are interested in
THR options, including long-term substitution with
nicotine products, and which, if any, nicotine products
are acceptable to this population.
Methods
Seven focus groups and three individual interviews
(n = 27) were conducted between October 2014 and
March 2015 at clinic and community venues in Inala, a
Brisbane suburb with an Indigenous population of
6.6% compared with 2.5% nationally [20]. Inala is one
of Brisbane’s most disadvantaged suburbs [21]. We
followed the National Health and Medical Research
Council guidelines for ethical Indigenous research.
Consultation was held and support given by the Inala
Community Jury for Aboriginal and Torres Strait
Islander Health Research, which was established to
encourage community participation in the Southern
Queensland Centre of Excellence in Aboriginal and
Torres Strait Islander Primary Health Care’s (CoE)
research agenda to ensure health research undertaken in
the community is ethically sound, culturally appropriate
and locally supported using a safe, meaningful, equitable
and transparent process [22]. The CoE provides clinical
services (e.g. general practitioner, visiting medical
specialist and allied health), community health services
(e.g. health promotion and education) and also conducts
research. Ethics approval was granted by the Metro
South Human Research Ethics Committee and The
University of Queensland Behavioural and Social
Sciences Ethical Review Committee.
Participants
Participant inclusion criteria were as follows: Currently
smoking daily; aged 16 or over; identify as Aboriginal
and/or Torres Strait Islander; sufﬁcient English ﬂuency
and capacity to understand the participant information,
consent process and to be able to participate in a focus
group or individual interview; and an existing client of
the CoE. Studies of these clients have found smoking
rates of between 55% and 67% [23–25]. We recruited
smokers from the CoE smoking cessation service list,
ﬂyers distributed in theCoE clinic and personal approach
byCoE staff to clinic orCoE community event attendees.
Participationwas open to everyonewhomet the inclusion
criteria, with emphasis on gaining equal numbers of male
and female participants. Verbal and written explanations
of the study were provided, and participants signed
consent forms. Participants were compensated for their
time with a $40 gift voucher and were offered an NRT
product of their choice (from current over-the-counter
products). Those interested in smoking cessation were
given information about available services.
Data collection
Interviews (focus group and individual) ran for up to
70 min facilitated by up to three researchers, including
one who is Indigenous and is the CoE’s tobacco
treatment specialist (KY). The other co-facilitators were
non-Indigenous university-based public health
researchers (CG and PF). Three individual interviews
were held for participants who could not attend a focus
group. Separate gender groups were established to
acknowledge gender roles embedded throughout urban
Aboriginal society where discussion of particular issues
may be less appropriate in mixed gender groups. Focus
groups provided the opportunity for in-depth exploration
of the topic through interactions between participants.
This is relevant to nicotine product use, which may be
inﬂuenced by perceived social acceptability and
desirability of such use [3].
The same semi-structured interview schedule was used
in the focus groups and individual interviews (Data S1).
The initial questions centred on smoking, including
positive and negative aspects, followed by a discussion
of quit attempts, knowledge and perceptions of available
supports, and knowledge of and experience with nicotine
products. Current NRTs (patch, gum, lozenge,
dissolvable oral strip, mouth spray and inhalator) and
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novel products (metered dose inhaler, ‘cigalike’ e-
cigarette, reﬁllable tank-style vaporiser, e-pen and snus)
were demonstrated to prompt discussion and ensure
common understanding of products. All interviews
investigated the acceptability of using nicotine products
as short-term quitting aids (i.e. a standard treatment
course of 8–12 weeks) or as long-term cigarette
substitutes (i.e. using it for an unspeciﬁed time with no
deﬁnitive end-date). A short survey collected
demographics, smoking history, dependence on smoking
(time to ﬁrst cigarette and number of cigarettes per day to
calculate the heaviness of smoking index) and interest in
trying each product. This was measured on a three-point
scale of the following: very likely to try, maybe would try
and would never try.
Data analysis
All interviews were digitally recorded and professionally
transcribed verbatim. Following the method described
by Braun and Clarke [26], the initial phase of coding
included listening to the recordings and reading the
transcripts to gain an overview of the data. Key phrases
and sections were identiﬁed and grouped, based on
patterns identiﬁed by the coders, combining both
deductive and inductive approaches. These were
categorised into themes reﬂecting topics covered in the
interview schedule: what is good and bad about
smoking, quitting experiences, views on long-term
substitution and views on each demonstrated product.
Transcripts were coded separately by KY and CG.
Two experienced qualitative researchers not involved
in the data collection (AM and LF) reviewed the
transcripts and the draft manuscript. Results were
discussed by all authors who provided further input into
coding and categorisation of data to enhance rigour and
inter-rater triangulation [27]. The quantitative data
were analysed descriptively (counts and percentages
calculated) in IBM SPSS V23. IBM Corp, Armonk,
NY, USA.
Results
Participants reﬂected a cross-section of the community
with a range of ages, education levels and both men and
women represented. Most participants (74%) scored
medium to high on the heaviness of smoking index [28]
(Table 1). The size of the focus groups ranged from two
to seven participants (Table 2).
Smoking and quitting experiences
Discussions about smoking and quitting included the
following: the entrenched nature of smoking in daily life;
use for stress relief; and quitting challenges. Smoking and
quitting were strongly linked to the social context of
participants’ lives as they described the dominance of
smoking across families, generations and community. A
participant noted ‘brought up with it’ [Group 1, male
participant number 1 (G1, M1)]. Smoking was also
linked to social connections.
… like being around it just, makes you, if they are smoking,
I will smoke…. You know being around the other mob who
are smoking so you think, I0ll have a smoke too. [G6, M3]
Many participants, particularly in female focus groups,
identiﬁed traumatic experiences andmultiple chronic life
stressors, including caring for immediate and extended
Table 1. Participants characteristics
N (%)
Gender
Male 17 (63%)
Female 10 (37%)
Age
<26 10 (37%)
26–45 12 (44%)
>45 4 (5%)
Education
Year 10 or less 18 (67%)
Year 12 6 (22%)
Post-secondary 3 (11%)
Heaviness of smoking index
Low 6 (22%)
Medium 14 (52%)
High 6 (22%)
Ever used NRT
Yes 16 (59%)
No 11 (41%)
NRT, nicotine replacement therapy.
Table 2. Participants in focus group (G) and individual
interviews (I)
Group/interview Gender N
G1 Male 2
G2 Female 7
G3 Male 2
I4 Male 1
I5 Female 1
G6 Male 4
G7 Male 4
G8 Male 3
I9 Male 1
G10 Female 2
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family, living on a tight budget, and having to go without
when ﬁnances ran out. Smoking was seen as providing
relief and creating a sense of calm in response to these
challenges.
… it’s that calm, it’s like a medicine. [G2, F7]
For some participants, particularly men, the
addictiveness of smoking was cited as the key reason they
smoked. One expressed this as:
I reckon it’s just an addiction. [G6, M1]
Experience with nicotine products and smoking cessation
medications
Most participants knew about nicotine patches; however,
fewer were familiar with the other nicotine products.
Sixteen participants (59%) had previously used NRT
(Table 1), with nicotine patches (37%) the most
commonly used, then gum (26%), inhalator (26%),
mouth spray (22%), lozenge (7%) and dissolvable oral
strips (7%). Some had experienced NRT while in
smoke-free health-care facilities. Others had used NRT
subsidised through the ‘close the gap’ program for a quit
attempt.
Attributes of nicotine products affecting their acceptability
Some reported positive experiences withNRT, including
controlling cigarette cravings, but most reported negative
experiences, particularly concerning taste: ‘horrible’
[gum, mouth spray; G7, M2], ‘disgusting’ [mouth spray;
I5, F1], ‘yuck’ [lozenge; G7, M3], ‘like chewing rubber’
[gum; G6, M2].
The inhaler [inhalator] was the only thing, that tasted like
shit, and sort of worked for about half an hour, and then
you’d think, “Oh, I don’t want that shit taste, I’m going
to have a cigarette.” [G2, F1]
Some products, particularly patches, were seen as
ineffective for craving relief: ‘I’d have two on, and I’d
have a White Ox [brand of loose tobacco]’. [G2, F1].
Side effects were also reported: ‘I had really bad
nightmares’. [G2, F6]
Those whose previous experience with existing
smoking cessationmedications had proved disappointing
expressed scepticism about other potential substitutes.
You’re still on strong smokes and then you give them that,
and that is weak. [G6, M1]
Needing to learn new routines associated with some
products was viewed as a barrier to uptake.
Facilitator: So do you think that [metered dose inhaler]
would be useful for people quitting smoking?
Respondent: Yeah I reckon. I reckon it would but I
reckon people would get annoyed with just the routine
of taking it out and putting it in, and then letting it
lay up and then waiting and…. [I9, M1]
The snus was rejected by many. The method of use
and appearance was generally unacceptable, described
as ‘feral’ by one participant [G2, F3]. More broadly, it
was viewed as disconnected from the experience and
sensation of smoking.
Forme, smoking is actually blowing out the smoke. [G1,M2]
Social acceptance of nicotine products
Community and family attitudes towards the appearance
and visibility of the product were important
considerations around using current or novel products.
Using alternatives to tobacco could be seen as stepping
outside the community norm of smoking. Teasing or
being criticised was feared if the product did not look
acceptable.
‘No you’d feel stupid with it. [e-cigarette]’ [G2, F8]
‘Oh could you just imagine sitting around with a group
of our mob (laughs) you’d never live it down’. [G2, F6]
‘No no oh no’! [G2, F1]
This attitude may have caused women to prefer a more
discreet product that did not produce a visible mist, such
as the inhalator:
That thing [inhalator], you can hold it like that [hidden in
hand] and nobody knows that you’re actually doing
something. [G2, F1]
One participant disliked the inhalator’s appearance:
It looks like a med [brand of tampon] too. [I5, F1]
Another participant suggested the inhalator could be
made more socially acceptable to Indigenous people by
adding artwork.
If you really want, you know, Indigenous people to give it a
shot… paint it black, yellow, red, paint it the colours of the
ﬂag and put some artwork on it or something. [G1, M2]
The current laws inQueensland that prohibit vaping in
smoke-free areas were a potential barrier to use of
e-cigarettes and other vaporiser devices.
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We’d still be separated like when we go outside to have a
normal cigarette. [G1, F2]
Concerns about risk to children
Both male and female participants raised concerns about
the potential attractiveness of e-cigarettes and other
vaporiser devices to children as a ‘gateway’ to smoking
tobacco.
Facilitator 2:And do you think there could be any problems
with using this product?
Respondent 1:Well if the kids found out about it you
know they’d, they might have a go at it and then might
start with the real smokes. [G1, M1]
Facilitator 2: Yeah, so you think that might be
attractive to children?
Respondent 1: Yeah, children. See you smoking hey,
yeah [G1, M1]
Other social inﬂuences
Advice fromhealth practitioners and personal testimonial
from community members about nicotine products
appeared highly inﬂuential to trying a product.
Furthermore, assistance from a medical practitioner was
commonly cited as an available cessation support. One
participant was reluctant to try any nicotine products
without medical practitioner endorsement.
I prefer to go throughmy doctor before I try anything, get the
doctor’s consent. [G10, F2]
Lay knowledge and experience was also highly valued.
So, I think you hear other people that it’s been, it’s worked
for, other people start going well, I might give it a shot. So I
think, yeah, you get a couple of people to say, yeah,
advocate for it and say, yeah, it’s great, it works, it helped
me, then I think, yeah, that’s how you sort of promote it.
[G1, M2]
Willingness to try products
In the quantitative survey, most participants indicated
willingness to try a nicotine product (Table 3). Eleven
(65%) of the men and nine (90%) of the women indicated
they would be very likely to try at least one current NRT
product if given the opportunity. If novel products
(metered dose inhaler, cigalike, tank vaporiser and snus)
are included, then all but one participant indicated that
they would be very likely to try a nicotine product.
Long-term substitution
We deﬁned long-term substitution as using nicotine
products in a similar way to cigarettes, for an unspeciﬁed
time with no deﬁnitive end-date. Participants viewed the
taste of NRT as a barrier to long-term substitution.
Table 3. Likelihood of trying each product if given the opportunity
Product Very likely to try, n (%) Maybe would try, n (%) Would never try, n (%)
Men (n = 17)
Cigalike e-cigarette 14 (82) 3 (18) 0 (0)
Metered dose inhaler 5 (29) 10 (59) 1 (6)
Inhalator 8 (47) 6 (35) 2 (12)
Tank vaporiser 7 (41) 5 (29) 4 (24)
Dissolvable oral strip 2 (12) 8 (47) 6 (35)
Lozenge 2 (12) 7 (41) 6 (35)
Patch 1 (6) 8 (47) 6 (35)
Mouth spray 1 (6) 8 (47) 7 (41)
Gum 2 (12) 4 (24) 10 (59)
Snus 1 (6) 3 (18) 11 (65)
Women (n = 10)
Inhalator 8 (80) 1 (10) 1 (10)
Mouth spray 5 (50) 3 (30) 2 (20)
Dissolvable oral strip 4 (40) 3 (30) 2 (20)
Patch 1 (10) 6 (60) 3 (30)
Metered dose inhaler 4 (40) 2 (20) 4 (40)
Lozenge 1 (10) 5 (50) 3 (30)
Tank vaporiser 1 (10) 4 (40) 5 (50)
Gum 0 (0) 4 (40) 5 (50)
Cigalike e-cigarette 1 (10) 2 (20) 7 (70)
Snus 1 (10) 2 (20) 7 (70)
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I don’t think any of these particularly taste really good that
you’d want to continue, I think if you just use it for its
purpose…. [G1, M2]
Those not interested in long-term substitution either
indicated no current interest in quitting smoking
because of current life circumstances or it conﬂicted
with their desire to achieve abstinence.
Respondent:Are you saying do that for the rest of your life
instead of real smokes? [G2, F7]
Facilitator: Well, you could. Yeah, so would that be
appealing… ?
Respondent: If I want to give up, I don’t want to keep
using anything. [G2, F7]
Respondent: No, no, me neither. [G2, F5]
For many, short-term use of a nicotine product (i.e.
for the recommended treatment timeframes) was
acceptable, but indeﬁnite use was not, because this still
involved being addicted.
Facilitator: Do you think that would be useful as a long-
term replacement for cigarettes?
Respondent: I don’t. [G2, F1]
Respondent: It’s just another addiction. [G2, F5]
Attributes of acceptable substitute nicotine products
To identify the attributes of an acceptable cigarette
substitute, we coded the transcripts into factors
participants associated with reasons for smoking and
quitting. We then coded the discussions about the
nicotine products for attributes that would encourage
use of the products and mapped these against smoking
or quitting factors.The remaining product attributeswere
then coded into whether divergent views were expressed
about the desirability of the attribute or not (Figure 1).
Many factors that were identiﬁed in the discussions as
reasons for smoking could potentially be addressed by
switching to a less-harmful nicotine product, such as
addressing addiction to nicotine, providing a nicotine
‘kick’ and a tool for ‘stress relief’. In addition to effective
nicotine delivery, an acceptable cigarette substitute
would need to be viewed by the community as ‘normal’,
easy to use, taste pleasant and gain the endorsement of
people within the community. There were divergent
views on how closely an acceptable substitute product
mimicked smoking, such as the appearance of the
product and whether it produced a visible vapour.
Similarly, many of the reasons to quit smoking could also
potentially be addressed by switching to an alternative
less-harmful nicotine product, such as providing a health
beneﬁt, avoiding social exclusion (due to having to go
outside to smoke), saving money and recommendations
from medical practitioners, if the substitute was one that
could be used anywhere, was less expensive than
cigarettes and approved as a medicine. However, desire
for freedom from addiction, which was a quit motivation
for some participants, conﬂicted with the concept of
long-term substitution.
Discussion
Discussions with smokers in this urban Indigenous
community, located in an area of high disadvantage,
revealed four main themes: (i) the barriers to quitting
smoking (e.g. use for stress relief, addiction and the
entrenched nature of smoking within families) and
motivators to quit (e.g. cost, social exclusion due to
Figure 1. Attributes that make a cigarette substitute acceptable or not acceptable.
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indoor smoking bans, and for health improvement); (ii)
participants’ experiences with and views on different
nicotine products, including existing NRT products
and novel products, such as e-cigarettes; (iii) product
attributes (e.g. ﬂavour, appearance and nicotine
delivery); and (iv) social inﬂuences (e.g. community
acceptance) and how these address the drivers of
smoking and motivations to quit will determine whether
a particular nicotine product is likely to be an acceptable,
either as a short-term cessation aid or a long-term
cigarette substitute. There were generally common views
about the desirability of some attributes (e.g. pleasant
ﬂavour), but divergent views were evident on the
desirability of others (e.g. visible vapour).
Smoking for ‘stress relief’ was evident as a reason for
smoking and consistent with other research identifying
signiﬁcant degrees of trauma and chronic life stress that
many Indigenous people face in daily life. For example,
most (83%) Indigenous daily smokers in a national
survey agreed that smoking calmed them down when
stressed or upset [4]. This presents a substantial barrier
to quitting. Finding alternative ways to deal with stress
to prevent relapse was identiﬁed as important among
Indigenous ex-smokers in a previous study in Inala
[3]. Some participants saw potential value in swapping
to a less harmful nicotine product, if it provided the
same stress relief as cigarettes do. Much of the ‘stress
relief’ attributed to smoking is largely relief of nicotine
withdrawal symptoms and smokers frequently conﬂate
these two [29]. Increasing smokers’ understanding that
quitting smoking can reduce feelings of stress,
depression and anxiety in the long run may assist in
addressing this barrier to quitting [30].
The concept of long-term substitution of cigarettes
with less-harmful nicotine products was new to
participants and some expressed interest in this strategy.
Discussion of long-term substitution did not appear to
reduce interest in achieving abstinence among those
aspiring to quit. Consistent with other research
[3,31,32], our discussions found that many valued
freedom from addiction and more appeared interested
in using nicotine products for a limited time for this
goal than for long-term substitution. Most of our
participants had accessed NRT at low or no cost
through government subsidisation or during a stay in a
health-care facility. Consistent with other research, cost
does not appear to be a barrier to short-term use [13].
However, cost becomes an important consideration for
use beyond recommended treatment timeframes and
for unsubsidised and unapproved products, like e-
cigarettes.
Participants discussed laws covering smoking in public
places and use of e-cigarettes. Current Queensland laws
apply the same restrictions on sale and public use of
vaping products as on smoked tobacco products.
Participants indicated that people would probably
continue to smoke if novel nicotine products carried the
same restrictions. This may explain preferences towards
some of the therapeutic products that are not subject to
similar restrictions on public use.
In addition to the perceived ineffectiveness of some
products, the unpleasant taste of existing NRTs is a
major factor limiting usefulness as both short-term
cessation aids and long-term substitutes. This appears
to be a major barrier to greater uptake of the inhalator.
Approved NRTs, such as the inhalator, have some
advantages over e-cigarettes, including high-quality
assurance in manufacturing, an established safety proﬁle
and legal status in Australia, where there are few legal
options for accessing e-cigarettes containing nicotine
[33]. However, the conservative design of NRTs,
consistent with their role as a medicine [34], limited their
appeal to participants and their perceived usefulness both
as a short-term cessation aid and for long-term
substitution. Researchers have concerns about the safety
of inhaling ﬂavourings used in e-liquids into the lung
[35]. However, unlike e-cigarette aerosol, the inhalator’s
vapour is not drawn deeply into the lung, reducing this
potential risk. Novel nicotine products, like vaping
devices, are available in a wide range of ﬂavours, and this
was viewed as a favourable attribute; therefore,
enhancement of the ﬂavours of NRTs may make them
more consumer-friendly.
Apart from the ﬂavour, the inhalator was widely viewed
as an appealing and useful short-term cessation aid.
Some participants indicated it could be an acceptable
long-term cigarette substitute. Favourable attributes
were as follows: being discreet, useable indoors, which
avoids separation from others, and mimics the hand-to-
mouth action of smoking. While others have described
the inhalator’s appearance as ‘tampon like’ [36], only
one participant in our study used this description.
Another participant suggested improvements of the
inhalator appearance by adding artwork or recolouring
it may increase its appeal.
E-cigarettes are gaining popularity, with 20% of
Australian smokers having tried them and 7% currently
using them [37]. In the UK, prevalence of e-cigarette
use now exceeds that of NRTs [14]. Like other
disadvantaged smokers in Australia [38], some
participants had experimented with e-cigarettes. In our
study, the novel products, including e-cigarettes,
received a mixed response. There was most interest in
trying inhaled forms of nicotine, including existing
products (inhalator) and particularly novel products (e-
cigarette, metered dose inhaler and tank-style vaporiser)
among men who valued inhaling and exhaling visible
‘smoke’ as part of the smoking experience. Fewer
women were interested in using the e-cigarette or the
tank-style vaporiser. This was similar to research with
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disadvantaged groups in the UK, where women
indicated a reluctance to use e-cigarettes in public [32].
The lack of interest in snus among this sample may
reﬂect the low prevalence of non-smoked tobacco use in
urban areas. However, in some rural and remote areas,
chewing tobacco was a traditional practice among some
Indigenous peoples and is still prevalent today [39].
Future research could explore whether the practice of
chewing tobacco in rural and remote regions of
Australia inhibits smoking by providing an alternative
delivery method and whether low-nitrosamine tobacco
products, such as snus, would be an acceptable substitute
in these communities.
While there is limited evidence on the effectiveness of
NRT among Indigenous Australians, a small trial of free
nicotine patches found that of the 40 smokers who chose
the patches, 10% had quit smoking at 6 months
compared with 1% of the 71 who chose the brief
intervention only [40]. It was noted in that trial that no
participants completed the full recommended course of
patches. Previous research among a national sample of
Indigenous Australians found that less than 10% of those
who had used NRT had used it for at least 2 months with
around half continuing for a week or less [12]. Early
discontinuation suggests few Indigenous smokers are
willing to use existing products for extended periods.
Reasons may include views about the risk of using
‘medicines’, and reducing risk by using as little as
possible, concerns about transferring addiction to NRT,
side effects, unpleasant taste, unsatisfying experience or,
alternatively, feeling the product has performed its job
and is no longer required. Smokers should be
encouraged to use nicotine products for the full
recommended course of 12 weeks. However, use beyond
12 weeks may be beneﬁcial for those who are unable to
sustain abstinence after discontinuation of treatment.
This is likely to require improvements in taste,
appearance and nicotine delivery in available products.
Products also need to be presented to people as a realistic,
attractive and lower-risk alternative to cigarettes [34].
Our study suggests that for some smokers in this
population (particularly men), access to nicotine-
containing e-cigarettes could increase the number of
urban Australian Indigenous smokers interested in
switching to a nicotine product. This has implications
for Australia and other countries with highly restrictive
laws concerning nicotine [33].
Other factors inﬂuence acceptability of particular
nicotine products. Potential impact on children was an
important consideration raised by some participants.
For these participants, NRTs, such as the inhalator, had
greater acceptability than e-cigarettes, which were seen
as potentially attractive to children.
Some participants preferred to quit without assistance.
Similar ﬁndings have been reported in other studies with
both Indigenous people and general population smokers
[3,12,31].While there is good evidence from randomised
controlled trials that pharmaceutical cessation aids,
particularly when combined with behavioural support,
can improve the likelihood of success of a quit attempt
[41], personal preferences and values, including feelings
of personal achievement from quitting cold turkey should
be acknowledged [31]. Nevertheless, we found 74% of
participants indicated they would be very likely to try an
NRT given the opportunity; a further 18.5% indicated
they ‘maybe’would try one. This level of interest is higher
than found in a national survey of Indigenous smokers,
in which only 54% of the 1124 dependent smokers
indicated they were interested in using NRT in the
future [12]. In our study, few participants were familiar
with the full range of NRTs available, so seeing new
products may have increased interest.
Strengths and limitations
This study was the ﬁrst to obtain the views of urban
Indigenous smokers, a priority population experiencing
disproportionately high levels of tobacco-related harms,
on THR and the acceptability of both NRTs and novel
nicotine products. Our sample was of modest size;
however, it captured a broad range of views from
participants of different ages, genders and smoking and
quitting experience. We believe data saturation was
reached as the same themes recurred, and collecting
more data was unlikely to produce new themes. The lead
researcher is an Indigenous woman with links into the
community, which provided an Indigenous perspective
for interviews and analysis. She is also the CoE’s tobacco
treatment specialist. As participants were recruited from
the CoE, this may have inﬂuenced the results. For
example, the importance of health practitioners
endorsing nicotine products emerged as a theme;
however, this may only be important to people in regular
contact with a health service, and some participants may
have emphasised this as a form of social desirability bias,
especially for the focus groups held at the CoE’s
premises. Some may have felt it would be inappropriate
to admit to not wanting to quit smoking. Similarly,
participants may have indicated interest in the NRTs
because of the health service context. Conversely,
familiarity with the researcher may have produced higher
levels of comfort and disclosure than may otherwise have
occurred. Indeed, many participants were comfortable
expressing negative views about some of the products
discussed (e.g. ‘shit taste’, ‘I did not like it’, ‘looks like a
med’). As with other qualitative research, our ﬁndings
cannot necessarily be generalised to the wider Indigenous
population and further quantitative research in multiple
communities is needed to determine representativeness.
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Conclusions
Participants faced substantial barriers to quitting,
including high levels of chronic stress and traumatic
experiences. We found substantial interest in trying
nicotine products, particularly for short-term use, with
some participants interested in long-term substitution if
an acceptable product was available. NRTs and some
novel nicotine products could potentially fulﬁl the role
that cigarettes currently occupy; however, improvements
in current NRTs (e.g. ﬂavours) and access to novel
products, such as e-cigarettes, may be needed to make
longer-term use attractive.
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